Tesaro — Technical Presentation (February 2013)
10 slides from Tesaro's technical presentation, Feb 14, 2013
Slide 1: Niraparib (PARP Inhibitor) Phase 3 Pivotal Program for Ovarian Cancer
Niraparib (PARP Inhibitor) Phase 3 Pivotal Program for Ovarian Cancer February 14, 2013
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are forward-looking statements reflecting the current beliefs and expectations of management. Forward-looking statements are sometimes identified by words such as “plan,” “may,
Slide 3: Phase 1 Design and Objectives Overview
Phase 1 Design and Objectives Overview Trial Design Objectives First in human, open-label, Phase 1 study Oral once daily dosing; two part study Initial results (n=80) reported ASCO 2011 Dose escalation and expansion study (n=104) evaluated 30mg – 400mg of niraparib (MK-4827) Primary Objectives: Eval
Slide 4: Niraparib Phase 1 Study Results
Niraparib Phase 1 Study Results Initial reported activity (n=80); mean prior regimens of 4.5 Overall clinical activity PR 12/80 (15%); 10 ovarian, 2 breast SD 24/80 (30%); ovarian, breast, lung, other SD > 12 weeks 18/80 (22.5%) Clinical activity in ovarian patients (n=39 evaluable) PR 10/39 (26%);
Slide 5: Considerations for a Registration Study
Considerations for a Registration Study A well tolerated dose and schedule that provided for clinical activity were identified in the Phase 1a/b study Current formulation is acceptable for long term use (3 capsules, dosed once daily) Clinical Enrichment: Patients with relapsed platinum sensitive HGS
Slide 6: Considerations for Patient Enrichment
Considerations for Patient Enrichment High Grade Serous Ovarian Cancer (HGSOC): 50% of HGSOC patients are deficient in HR DNA repair1 Approximately one-half of these are patients are gBRCAmut Platinum Sensitivity in Ovarian Cancer: HR-deficient cells are more likely to be platinum sensitive because
Slide 7: PARP inh. Ovarian Maintenance POC
PARP inh. Ovarian Maintenance POC Ledermann J., et. al., N Engl J Med 2012 Median PFS: PARPi (8.4 months) vs. Control (4.8 months) Overall HR = 0.35; gBRCAmut HR = 0.10
Slide 8: Phase 3 Design and Objectives Overview
Phase 3 Design and Objectives Overview Trial Design Objectives HGSOC, platinum sensitive, relapsed, in response to most recent platinum regimen Two independent cohorts: gBRCAmut (n=180) AND non-gBRCAmut (n=180) Double blind, placebo controlled, international study Each cohort is independently random
Slide 9: Niraparib Phase 3 Design Specifics
Niraparib Phase 3 Design Specifics High Grade Serous Ovarian Cancer, Platinum Sensitive, Relapsed placebo gBRCAmut 2:1 randomization Endpoint assessment Niraparib placebo 2:1 randomization Endpoint assessment Response to platinum treatment Non-gBRCAmut Niraparib
Slide 10: Niraparib Summary
Continuous dosing with 300mg oral niraparib is well tolerated and resulted in clinical activity in a large Phase 1 dose escalation/cohort expansion study Patients with platinum sensitive HGSOC experience clinical benefit from treatment with PARP inhibitors, including niraparib, regardless of gBRCAmu